Prestige Consumer Healthcare Inc.
HealthcareNYSE:PBH · New York Stock Exchange
+$0.25 today
Vol 0.44M · Avg 0.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.1%
avg 10.3%
ROIC
6.6%
avg 5.4%
ROA
5.4%
avg 3.9%
Analysis
ROE is currently the strongest return metric at 10.1% versus its period average of 10.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ronald Lombardi | Chairman, President & Chief Executive Officer | $2.19M | — | 62 | $373,465.00 | 0.79% |
Christine Sacco | Chief Financial Officer & Chief Operating Officer | $1.27M | — | 50 | $71,636.00 | 0.15% |
Adel Mekhail | Executive Vice President of Marketing & Sales | $861,557.00 | — | 64 | $25,703.00 | 0.05% |
William C. P'Pool | Senior Vice President, General Counsel & Corporate Secretary | $860,439.00 | — | 61 | $28,149.00 | 0.06% |
Jeffrey Zerillo | Senior Vice President of Operations | $531,270.00 | — | 64 | $41,810.00 | 0.09% |
Dean Siegal | Director of Communications | — | — | — | — | — |
Jose Luis Rosado | Senior Vice President of Quality & Regulatory Affairs | — | — | — | $3,436.00 | <0.01% |
Philip David Terpolilli | Director of Investor Relations | — | — | — | $22,721.00 | 0.05% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$424,423.73
Net Sentiment
$424,423.73
Net selling
Most Active
Zerillo Jeffrey
7 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $424,423.73 over the last 12 months. That adds up to net selling of $424,423.73. Zerillo Jeffrey was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +14.0% | +7.9% (15yr)1 analysts |
| Revenue | N/A | N/A | +8.9% | +4.0% (15yr)1 analysts |
| Net Income | N/A | N/A | +15.1% | +7.2% (15yr)1 analysts |
| EBIT | N/A | N/A | +10.7% | +1.8% (15yr)1 analysts |
Analysis
Recent growth has been strongest in Net Income at +15.1% over three years. Forward estimates point to EPS at +7.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
ICU Medical, Inc.
NASDAQ:ICUI
$3.55B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.95B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
Who manages PBH?
Prestige Consumer Healthcare Inc. (PBH) lists 8 active executives. The top listed executive is Dean Siegal, Director of Communications.
Are PBH insiders buying or selling?
Recent insider activity shows net selling of $28.38M.
Explore More
Continue the stock analysis
Jump to another research area for this company.